Related Experiment Videos
Synaptic structure and function in transgenic APP mice
1Department of Neurology, University of Minnesota, Box 295 UMHC, 420 Delaware Street S.E., Minneapolis, Minnesota 55455, USA. hsiao005@tc.umn.edu
Annals of the New York Academy of Sciences
|February 24, 2001
Summary
Transgenic mice models of Alzheimer's disease (AD) show amyloid plaques and cognitive decline but no neuron loss in the hippocampus. Further electrophysiological studies are needed to understand AD
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder characterized by amyloid plaques and cognitive impairment.
- Transgenic mouse models are crucial for investigating AD's molecular and structural underpinnings.
Purpose of the Study:
- To investigate the relationship between amyloid plaques, cognitive deficits, and neuronal/synaptic integrity in a specific mouse model of AD.
- To identify potential cellular or molecular changes that occur independently of overt neuronal loss in early-stage AD.
Main Methods:
- Utilized transgenic mice aged 12 to 18 months exhibiting AD-like pathology.
- Assessed cognitive function and examined the CA1 hippocampal subfield for neuronal and synaptic loss.
- Considered the utility of electrophysiological studies for further investigation.
Main Results:
- Transgenic mice displayed amyloid plaques and impaired cognition.
- No significant neuronal or synaptic loss was observed in the CA1 hippocampal subfield of these mice.
- The findings suggest that cognitive impairment in this model precedes detectable neuronal degeneration.
Conclusions:
- Early-stage Alzheimer's disease models in mice can exhibit cognitive deficits without apparent neuronal loss in key hippocampal regions.
- Electrophysiological studies are proposed as a valuable method to explore the functional consequences of amyloid pathology that may not be visible structurally.
- Further research is warranted to elucidate the precise mechanisms driving cognitive impairment in the absence of significant neurodegeneration.